These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 21465637)

  • 41. The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy.
    Navari RM; Nagy CK; Gray SE
    Support Care Cancer; 2013 Jun; 21(6):1655-63. PubMed ID: 23314603
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Safety and efficacy of nabilone for acute chemotherapy-induced vomiting prophylaxis in pediatric patients: A multicenter, retrospective review.
    Polito S; MacDonald T; Romanick M; Jupp J; Wiernikowski J; Vennettilli A; Khanna M; Patel P; Ning W; Sung L; Dupuis LL
    Pediatr Blood Cancer; 2018 Dec; 65(12):e27374. PubMed ID: 30051617
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Survey ranking of emetogenic control in children receiving chemotherapy.
    Small BE; Holdsworth MT; Raisch DW; Winter SS
    J Pediatr Hematol Oncol; 2000; 22(2):125-32. PubMed ID: 10779025
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Characterizing and assessing antiemetic underuse in patients initiating highly emetogenic chemotherapy.
    Mahendraratnam N; Farley JF; Basch E; Proctor A; Wheeler SB; Dusetzina SB
    Support Care Cancer; 2019 Dec; 27(12):4525-4534. PubMed ID: 30915567
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Prevention and treatment of antineoplastic drug-induced nausea and vomiting in pediatric onco-hematology: An update].
    Delmotte M; Mouffak S; Mongaret C; Michelet-Huot E; Roques G; Slimano F
    Bull Cancer; 2020; 107(7-8):800-812. PubMed ID: 32418660
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A comparison of oral ondansetron syrup or intravenous ondansetron loading dose regimens given in combination with dexamethasone for the prevention of nausea and emesis in pediatric and adolescent patients receiving moderately/highly emetogenic chemotherapy.
    White L; Daly SA; McKenna CJ; Zhestkova N; Leal C; Breatnach F; Smelhaus V; Hung IJ; Kowalczyk J; Ninane J; Mitchell T; Haigh C
    Pediatr Hematol Oncol; 2000 Sep; 17(6):445-55. PubMed ID: 10989464
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Prevention of chemotherapy-induced nausea and vomiting and the role of neurokinin 1 inhibitors: from guidelines to clinical practice in solid tumors.
    Di Maio M; Bria E; Banna GL; Puglisi F; Garassino MC; Lorusso D; Perrone F
    Anticancer Drugs; 2013 Feb; 24(2):99-111. PubMed ID: 23165435
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Emetogenic potential of antineoplastic agents based on clinical trials in Japan].
    Watanabe T; Handa S; Kato Y
    Gan To Kagaku Ryoho; 2015 Mar; 42(3):335-41. PubMed ID: 25812503
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Chemotherapy induced-vomiting--a practical guide for prevention and therapy].
    Jordan K; Voigt W; Schmoll HJ
    Dtsch Med Wochenschr; 2006 Aug; 131(34-35):1869-72. PubMed ID: 16915549
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind study.
    Rapoport BL; Jordan K; Boice JA; Taylor A; Brown C; Hardwick JS; Carides A; Webb T; Schmoll HJ
    Support Care Cancer; 2010 Apr; 18(4):423-31. PubMed ID: 19568773
    [TBL] [Abstract][Full Text] [Related]  

  • 51. 2016 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following multiple-day chemotherapy, high-dose chemotherapy, and breakthrough nausea and vomiting.
    Einhorn LH; Rapoport B; Navari RM; Herrstedt J; Brames MJ
    Support Care Cancer; 2017 Jan; 25(1):303-308. PubMed ID: 27815710
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Management of chemotherapy-induced nausea and vomiting.
    Dewan P; Singhal S; Harit D
    Indian Pediatr; 2010 Feb; 47(2):149-55. PubMed ID: 20228428
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Efficacy of Thalidomide in Preventing Delayed Nausea and Vomiting Induced by Highly Emetogenic Chemotherapy: A Randomized, Multicenter, Double-Blind, Placebo-Controlled Phase III Trial (CLOG1302 study).
    Zhang L; Qu X; Teng Y; Shi J; Yu P; Sun T; Wang J; Zhu Z; Zhang X; Zhao M; Liu J; Jin B; Luo Y; Teng Z; Dong Y; Wen F; An Y; Yuan C; Chen T; Zhou L; Chen Y; Zhang J; Wang Z; Qu J; Jin F; Zhang J; Jin X; Xie X; Wang J; Man L; Fu L; Liu Y
    J Clin Oncol; 2017 Nov; 35(31):3558-3565. PubMed ID: 28854065
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Assessing the benefits of anti-emetic innovation.
    Rees GJ
    Anticancer Drugs; 1993 Dec; 4 Suppl 3():5-7; discussion 7-8. PubMed ID: 8136517
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Guidelines for prophylaxis and treatment of chemotherapy-induced nausea and vomiting].
    Durand JP; Madelaine I; Scotté F
    Bull Cancer; 2009 Oct; 96(10):951-60. PubMed ID: 19734117
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A phase II trial of olanzapine for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier Oncology Group study.
    Navari RM; Einhorn LH; Passik SD; Loehrer PJ; Johnson C; Mayer ML; McClean J; Vinson J; Pletcher W
    Support Care Cancer; 2005 Jul; 13(7):529-34. PubMed ID: 15700131
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Poor chemotherapy-induced nausea and vomiting control in children receiving intermediate or high dose methotrexate.
    Vol H; Flank J; Lavoratore SR; Nathan PC; Taylor T; Zelunka E; Maloney AM; Lee Dupuis L
    Support Care Cancer; 2016 Mar; 24(3):1365-71. PubMed ID: 26335406
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Adherence to ESMO clinical recommendations for prophylaxis of chemotherapy-induced nausea and vomiting.
    Burmeister H; Aebi S; Studer C; Fey MF; Gautschi O
    Support Care Cancer; 2012 Jan; 20(1):141-7. PubMed ID: 21234609
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effectiveness of a single-day three-drug regimen of dexamethasone, palonosetron, and aprepitant for the prevention of acute and delayed nausea and vomiting caused by moderately emetogenic chemotherapy.
    Grunberg SM; Dugan M; Muss H; Wood M; Burdette-Radoux S; Weisberg T; Siebel M
    Support Care Cancer; 2009 May; 17(5):589-94. PubMed ID: 19037667
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Efficacy and safety of casopitant mesylate, a neurokinin 1 (NK1)-receptor antagonist, in prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based highly emetogenic chemotherapy: a randomised, double-blind, placebo-controlled trial.
    Grunberg SM; Rolski J; Strausz J; Aziz Z; Lane S; Russo MW; Wissel P; Guckert M; Wright O; Herrstedt J
    Lancet Oncol; 2009 Jun; 10(6):549-58. PubMed ID: 19428297
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.